Open AccessRecurrent herpes zoster in a rheumatoid arthritis patient treated with tofacitinib: A case report and review of the literature
Author(s) -
Qing-Xia Lin,
Hui-Juan Meng,
Yun-Yan Pang,
Qingzhi Yan
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i24.8703
Subject(s) - medicine , tofacitinib , janus kinase inhibitor , adverse effect , rheumatoid arthritis , dermatology , erythema , perineum , abdomen , surgery
Tofacitinib is an oral Janus kinase (JAK) inhibitor that is currently approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis (RA). Varicella zoster virus reactivation leading to herpes zoster (HZ) is an adverse effect of this drug; however, recurrent HZ at the same site is a rare clinical condition.